Cargando…

Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington’s disease

Proton magnetic resonance spectroscopy is a non-invasive method of exploring cerebral metabolism. In Huntington’s disease, altered proton magnetic resonance spectroscopy-determined concentrations of several metabolites have been described; however, findings are often discrepant and longitudinal stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lowe, Alexander J, Rodrigues, Filipe B, Arridge, Marzena, De Vita, Enrico, Johnson, Eileanoir B, Scahill, Rachael I, Byrne, Lauren M, Tortelli, Rosanna, Heslegrave, Amanda, Zetterberg, Henrik, Wild, Edward J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665272/ https://www.ncbi.nlm.nih.gov/pubmed/36382217 http://dx.doi.org/10.1093/braincomms/fcac258

Ejemplares similares

Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease
por: Ou, Zhen-Yi Andy, et al.
Publicado: (2021)

Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease
por: Byrne, Lauren M., et al.
Publicado: (2018)

Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease
por: Rodrigues, Filipe B., et al.
Publicado: (2021)

Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast MRI
por: Rodrigues, Filipe B., et al.
Publicado: (2019)

Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease
por: Lowe, Alexander J., et al.
Publicado: (2020)

Characterizing White Matter in Huntington's Disease
por: Gregory, Sarah, et al.
Publicado: (2019)

Neurofilament light protein in blood predicts regional atrophy in Huntington disease
por: Johnson, Eileanoir B., et al.
Publicado: (2018)

Lumbar puncture safety and tolerability in premanifest and manifest Huntington’s disease: a multi-analysis cross-sectional study
por: Hassan, Yara Refaat, et al.
Publicado: (2022)

The use of wearable/portable digital sensors in Huntington's disease: A systematic review
por: Tortelli, Rosanna, et al.
Publicado: (2021)

Dynamics of Cortical Degeneration Over a Decade in Huntington’s Disease
por: Johnson, Eileanoir B., et al.
Publicado: (2021)

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis
por: Byrne, Lauren M, et al.
Publicado: (2017)

Predicting clinical diagnosis in Huntington's disease: An imaging polymarker
por: Mason, Sarah L., et al.
Publicado: (2018)

Aberrant Striatal Value Representation in Huntington's Disease Gene Carriers 25 Years Before Onset
por: Nair, Akshay, et al.
Publicado: (2021)

Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease
por: Wijeratne, Peter A., et al.
Publicado: (2021)

Timing of selective basal ganglia white matter loss in premanifest Huntington’s disease
por: Zeun, Paul, et al.
Publicado: (2022)

A Multi-Study Model-Based Evaluation of the Sequence of Imaging and Clinical Biomarker Changes in Huntington’s Disease
por: Wijeratne, Peter A., et al.
Publicado: (2021)

Intellectual enrichment and genetic modifiers of cognition and brain volume in Huntington’s disease
por: Papoutsi, Marina, et al.
Publicado: (2022)

Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington’s Disease
por: Johnson, Eileanoir B., et al.
Publicado: (2017)

Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis
por: Scahill, Rachael I, et al.
Publicado: (2020)

Neurofilament light-associated connectivity in young-adult Huntington’s disease is related to neuronal genes
por: McColgan, Peter, et al.
Publicado: (2022)

Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington’s Disease
por: Mansoor, Nina M., et al.
Publicado: (2021)

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Fronto-striatal circuits for cognitive flexibility in far from onset Huntington’s disease: evidence from the Young Adult Study
por: Langley, Christelle, et al.
Publicado: (2021)

An image‐based model of brain volume biomarker changes in Huntington's disease
por: Wijeratne, Peter A., et al.
Publicado: (2018)

Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease
por: Wijeratne, Peter A., et al.
Publicado: (2020)

A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study
por: Lipsmeier, Florian, et al.
Publicado: (2022)

Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study
por: Johnson, Eileanoir B., et al.
Publicado: (2021)

Testing a longitudinal compensation model in premanifest Huntington’s disease
por: Gregory, Sarah, et al.
Publicado: (2018)

Diffusion imaging in Huntington’s disease: comprehensive review
por: Estevez-Fraga, Carlos, et al.
Publicado: (2021)

Huntington’s Disease Clinical Trials Corner: February 2018
por: Rodrigues, Filipe B., et al.
Publicado: (2018)

Huntington’s Disease Clinical Trials Corner: August 2018
por: Rodrigues, Filipe B., et al.
Publicado: (2018)

Brain Regions Showing White Matter Loss in Huntington’s Disease Are Enriched for Synaptic and Metabolic Genes
por: McColgan, Peter, et al.
Publicado: (2018)

Huntington’s Disease Clinical Trials Corner: June 2019
por: Rodrigues, Filipe B., et al.
Publicado: (2019)

Psychogenic non-epileptic seizures in early Huntington's disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children
por: Byrne, Lauren M., et al.
Publicado: (2022)

Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington’s disease
por: McColgan, Peter, et al.
Publicado: (2017)

Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?
por: Rodrigues, Filipe B., et al.
Publicado: (2017)

Quantification of huntingtin protein species in Huntington’s disease patient leukocytes using optimised electrochemiluminescence immunoassays
por: Hensman Moss, Davina J., et al.
Publicado: (2017)

Quantification of Intramyocardial Metabolites by Proton Magnetic Resonance Spectroscopy
por: Gillinder, Lisa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_knjv7lhqpd55ha533l1ks9oob8